2022
Optimizing the Design and Analysis of Future AKI Trials
Legrand M, Bagshaw SM, Koyner JL, Schulman IH, Mathis MR, Bernholz J, Coca S, Gallagher M, Gaudry S, Liu KD, Mehta RL, Pirracchio R, Ryan A, Steubl D, Stockbridge N, Erlandsson F, Turan A, Wilson FP, Zarbock A, Bokoch MP, Casey JD, Rossignol P, Harhay MO. Optimizing the Design and Analysis of Future AKI Trials. Journal Of The American Society Of Nephrology 2022, 33: 1459-1470. PMID: 35831022, PMCID: PMC9342638, DOI: 10.1681/asn.2021121605.Peer-Reviewed Original ResearchConceptsAKI trialsClinical trialsTrial participantsTrial designAKI clinical trialsPerioperative patient populationsComplex clinical syndromeRisk of morbidityPragmatic trial designTreatment effectsClinical trial planningImportant treatment effectsClinical trial analysisAKI preventionClinical courseClinical syndromePatient populationTrial interventionClinical questionsClinical trialistsAKITrial infrastructureTrial planningTrialsEfficient enrollmentAssociation of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study
Miano TA, Hennessy S, Yang W, Dunn TG, Weisman AR, Oniyide O, Agyekum RS, Turner AP, Ittner CAG, Anderson BJ, Wilson FP, Townsend R, Reilly JP, Giannini HM, Cosgriff CV, Jones TK, Meyer NJ, Shashaty MGS. Association of vancomycin plus piperacillin–tazobactam with early changes in creatinine versus cystatin C in critically ill adults: a prospective cohort study. Intensive Care Medicine 2022, 48: 1144-1155. PMID: 35833959, PMCID: PMC9463324, DOI: 10.1007/s00134-022-06811-0.Peer-Reviewed Original ResearchConceptsPiperacillin-tazobactamKidney biomarkersCystatin CAcute kidney injury riskProspective cohort studyCystatin C concentrationCystatin C measurementKidney function biomarkersCreatinine secretionAntibiotic initiationCohort studyProspective cohortIll adultsClinical outcomesAssociation of vancomycinAntibiotic treatmentTubular secretionCreatinine concentrationTreatment weightingResultsThe studyTrue injuryHigh incidenceCreatinineDay 14Early changes
2021
A neutrophil activation signature predicts critical illness and mortality in COVID-19
Meizlish ML, Pine AB, Bishai JD, Goshua G, Nadelmann ER, Simonov M, Chang CH, Zhang H, Shallow M, Bahel P, Owusu K, Yamamoto Y, Arora T, Atri DS, Patel A, Gbyli R, Kwan J, Won CH, Dela Cruz C, Price C, Koff J, King BA, Rinder HM, Wilson FP, Hwa J, Halene S, Damsky W, van Dijk D, Lee AI, Chun HJ. A neutrophil activation signature predicts critical illness and mortality in COVID-19. Blood Advances 2021, 5: 1164-1177. PMID: 33635335, PMCID: PMC7908851, DOI: 10.1182/bloodadvances.2020003568.Peer-Reviewed Original ResearchConceptsCritical illnessHealth system databaseNeutrophil activationCOVID-19Neutrophil activation signatureSevere COVID-19Intensive care unitGranulocyte colony-stimulating factorHigh mortality rateColony-stimulating factorSystem databaseHepatocyte growth factorClinical decompensationNeutrophil countImmune hyperactivationCare unitEarly elevationLipocalin-2Interleukin-8Longitudinal cohortClinical dataMortality ratePatientsIllnessActivation signature
2020
Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States
Flythe JE, Assimon MM, Tugman MJ, Chang EH, Gupta S, Shah J, Sosa MA, Renaghan AD, Melamed ML, Wilson FP, Neyra JA, Rashidi A, Boyle SM, Anand S, Christov M, Thomas LF, Edmonston D, Leaf DE, Walther C, Anumudu S, Arunthamakun J, Kopecky K, Milligan G, McCullough P, Nguyen T, Shaefi S, Krajewski M, Shankar S, Pannu A, Valencia J, Waikar S, Kibbelaar Z, Athavale A, Hart P, Upadhyay S, Vohra I, Green A, Rachoin J, Schorr C, Shea L, Edmonston D, Mosher C, Shehata A, Cohen Z, Allusson V, Bambrick-Santoyo G, Bhatti N, Mehta B, Williams A, Brenner S, Walters P, Go R, Rose K, Chan L, Mathews K, Coca S, Altman D, Saha A, Soh H, Wen H, Bose S, Leven E, Wang J, Mosoyan G, Nadkarni G, Pattharanitima P, Gallagher E, Friedman A, Guirguis J, Kapoor R, Meshberger C, Kelly K, Parikh C, Garibaldi B, Corona-Villalobos C, Wen Y, Menez S, Malik R, Cervantes C, Gautam S, Mallappallil M, Ouyang J, John S, Yap E, Melaku Y, Mohamed I, Bajracharya S, Puri I, Thaxton M, Bhattacharya J, Wagner J, Boudourakis L, Nguyen H, Ahoubim A, Kashani K, Tehranian S, Thomas L, Sirganagari D, Guru P, Zhou Y, Bergl P, Rodriguez J, Shah J, Gupta M, Kumar P, Lazarous D, Kassaye S, Melamed M, Johns T, Mocerino R, Prudhvi K, Zhu D, Levy R, Azzi Y, Fisher M, Yunes M, Sedaliu K, Golestaneh L, Brogan M, Kumar N, Chang M, Thakkar J, Raichoudhury R, Athreya A, Farag M, Schenck E, Cho S, Plataki M, Alvarez-Mulett S, Gomez-Escobar L, Pan D, Lee S, Krishnan J, Whalen W, Charytan D, Macina A, Chaudhry S, Wu B, Modersitzki F, Srivastava A, Leidner A, Martinez C, Kruser J, Wunderink R, Hodakowski A, Velez J, Price-Haywood E, Matute-Trochez L, Hasty A, Mohamed M, Avasare R, Zonies D, Leaf D, Gupta S, Sise M, Newman E, Abu Omar S, Pokharel K, Sharma S, Singh H, Correa S, Shaukat T, Kamal O, Wang W, Yang H, Boateng J, Lee M, Strohbehn I, Li J, Mueller A, Redfern R, Cairl N, Naimy G, Abu-Saif A, Hall D, Bickley L, Rowan C, Madhani-Lovely F, Peev V, Reiser J, Byun J, Vissing A, Kapania E, Post Z, Patel N, Hermes J, Sutherland A, Patrawalla A, Finkel D, Danek B, Arikapudi S, Paer J, Cangialosi P, Liotta M, Radbel J, Puri S, Sunderram J, Scharf M, Ahmed A, Berim I, Vatson J, Anand S, Levitt J, Garcia P, Boyle S, Song R, Zhang J, Woo S, Deng X, Katz-Greenberg G, Senter K, Sharshir M, Rusnak V, Ali M, Bansal A, Podoll A, Chonchol M, Sharma S, Burnham E, Rashidi A, Hejal R, Judd E, Latta L, Tolwani A, Albertson T, Adams J, Reagan R, Chang S, Beutler R, Monica S, Schulze C, Macedo E, Rhee H, Liu K, Jotwani V, Koyner J, Kunczt A, Shah C, Jaikaransingh V, Toth-Manikowski S, Joo M, Lash J, Neyra J, Chaaban N, Dy R, Iardino A, Au E, Sharma J, Sosa M, Taldone S, Contreras G, De La Zerda D, Gershengorn H, Hayek S, Blakely P, Berlin H, Azam T, Shadid H, Pan M, Hayer P, Meloche C, Feroze R, Kaakati R, Perry D, Bitar A, Anderson E, Padalia K, Donnelly J, Admon A, Flythe J, Tugman M, Chang E, Brown B, Leonberg-Yoo A, Spiardi R, Miano T, Roche M, Vasquez C, Bansal A, Ernecoff N, Kapoor S, Verma S, Chen H, Kovesdy C, Molnar M, Azhar A, Hedayati S, Nadamuni M, Shastri S, Willett D, Short S, Renaghan A, Enfield K, Bhatraju P, Malik A, Semler M, Vijayan A, Joy C, Li T, Goldberg S, Kao P, Schumaker G, Goyal N, Faugno A, Schumaker G, Hsu C, Tariq A, Meyer L, Kshirsagar R, Weiner D, Jose A, Christov M, Griffiths J, Gupta S, Kapoor A, Wilson P, Arora T, Ugwuowo U. Characteristics and Outcomes of Individuals With Pre-existing Kidney Disease and COVID-19 Admitted to Intensive Care Units in the United States. American Journal Of Kidney Diseases 2020, 77: 190-203.e1. PMID: 32961244, PMCID: PMC7501875, DOI: 10.1053/j.ajkd.2020.09.003.Peer-Reviewed Original ResearchConceptsPre-existing CKDChronic kidney diseaseIntensive care unitPre-existing kidney diseaseDependent chronic kidney diseaseKidney diseaseICU admissionDialysis patientsCare unitPre-existing chronic kidney diseaseSevere coronavirus disease 2019 (COVID-19) illnessCoronavirus disease 2019 illnessEffective COVID-19 therapiesIll COVID-19 patientsCOVID-19Dependent CKD patientsGray survival modelsMore dialysis patientsSevere COVID-19Acute liver injuryCOVID-19 patientsCOVID-19 therapyOutcomes of individualsCKD patientsHospital mortality